SB590885 (SB 590885; SB-590885) is a novel and potent B-Raf inhibitor with potential antineoplastic activity.

Agerafenib (formerly RXDX105; AC013773; RXDX-105; CEP-32496; AC-01377) is a potent and orally bioactive inhibitor of BRAFV600E and c-Raf with potential antitumor activity.

L-779450 is a potent, selective and ATP-competitive Raf kinase inhibitor (IC50 = 10 nM).

Vemurafenib (formerly PLX-4032; RG7204; RG-7204; RO5185426; RO-5185426; PLX4032; trade name: Zelboraf) is a potent and selective inhibitor of B-RafV600E mutated form with potential antineoplastic activity.

B-Raf inhibitor 1 is a novel, potent and selective Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.

AZ-628 (AZ628; AZ 628) is a novel, selective, and orally bioavailable Raf inhibitor with potential antineoplastic activity.

BI-882370 (BI 882370), structurally similar to vermurafenib, is a novel, highly potent and selective BRAF inhibitor with anticancer activity.

MLN2480 (BIIB-024; BSK1369; DAY-101; TAK-580; AMG-2112819) is an orally bioactive, potent and selective pan-Raf kinase inhibitor with potential anticancer activity.

Sorafenib Tosylate (BAY439006; BAY-439006; BAY549085; BAY-549085; Nexavar; SFN), the tosylate salt of Sorafenib which is an approved anticancer medication, is a potent multi-kinase inhibitor of Raf-1, B-Raf and VEGFR-2 with potential antineoplastic activity.

LUT014 is a novel, potent and topical B-Raf Inhibitor which is a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects.